Topical Lomefloxacin versus Topical Chloramphenicol in the Treatment of Acute Bacterial Conjunctivitis A. Agius-FernandezA. PattersonP. Sunder Raj Clinical Use 28 August 2012 Pages: 263 - 269
Comparison among Different Types, Dosages and Duration of Interferon Therapy in Chronic Hepatitis C Giampaolo BresciG. ParisiA. Capria Clinical Use 28 August 2012 Pages: 271 - 277
Pharmacokinetics and Efficacy of Low- Dose Ketoprofen in Postoperative Dental Pain R.A. SeymourP.J. KellyJ.E. Hawkesford Clinical Use 28 August 2012 Pages: 279 - 284
New Statistical Proposals to Evaluate the Benefit/Risk Ratio of Long-Term Treatment of Depression Philippe LehertM.F. Poirier-LittreA. Galinowski Clinical Use 28 August 2012 Pages: 285 - 295
Clinical Efficacy of Sparfloxacin in Mycoplasmal Pneumonia Takahiko HoriguchiSoichi TachikawaMisuzu Handa Clinical Use 28 August 2012 Pages: 297 - 302
Treatment of Long- Term Psychiatric Disorders in the Managed Care Environment Barbara DickeySharon-Lise T. NormandWilliam Fisher Clinical Pharmacoeconomics 28 August 2012 Pages: 303 - 308
Pharmacokinetic Profile of Epidurally Injected Bupivacaine in Awake Patients R.H.T. TaverneT.I. IonescuA. Van Dijk Clinical Pharmacokinetic 28 August 2012 Pages: 309 - 317
Clinical Pharmacokinetics of Ferric Natural Protein in Iron-Deficient Females A. López de OcárizM. SimónJ. Honorato Clinical Pharmacokinetic 28 August 2012 Pages: 319 - 325
Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens Vinodh R. Nannan PandayLaurence J.C. van WarmerdamJos H. Beijnen Clinical Pharmacokinetic 28 August 2012 Pages: 327 - 335
Recurrence Risk in Bipolar Manic- Depressive Disorders after Discontinuing Lithium Maintenance Treatment: An Overview Ross J. BaldessariniLeonardo Tondo Clinical Review 28 August 2012 Pages: 337 - 351
Effect of Adverse Drug Reactions on Length of Stay in Intensive Care Units E. VargasJ. SimónA. Moreno Pharmacovigilance 28 August 2012 Pages: 353 - 360
Encapsulation of Commercially Available Losartan for Blinding Purposes Does Not Affect its Bioavailability L. NymanKristina TaureP.-O. Lagerström Short Communication 28 August 2012 Pages: 361 - 365
